Georg Alexander Halder

°1967, Zwitser

Werkte aan:

University of Texas, MD Anderson Cancer Center, Houston, Texas, USA

 

Nieuwe thuishaven:

KU Leuven, Center for Human Genetics

Hij zal onderzoek voeren over “Discovery of novel growth control and cancer mechanisms” (De exploratie van nieuwe mechanismen voor groeicontrole en kanker).

Zijn Odysseus toelagen (Groep I) bedragen    4.896.472 EUR, verspreid over 5 jaar. Hij zal in Leuven aan het hoofd staan van een team van 12 onderzoekers.

 

Academische carrière:

o   Associate Professor, Department of Biochemistry and Molecular Biology, University of Texas, MD Anderson Cancer Center, Houston, Texas (2006-present)

o   Texas, MD Anderson Cancer Center, Houston, Texas (2000-2006)

o   Assistant Professor, Department of Biochemistry and Molecular Biology, University of

Postdoctoral Fellow, University of Wisconsin Madison (1996-2000)

o   Ph.D., Cell Biology, University of Basel, Switzerland (1990-1996)

 

Drie belangrijke publicaties:

Haider G, Callaerts F, and Gehring WJ (1995). Induction of ectopic eyes by targeted expression of the eyeless gene in Drosophila. Science 267,1788-1792,

Haider G, Polaczyk P, Kraus ME, Hudson A, Kim J, Laughon A, and Carroll 5 (1998). The Vestigial and Scalloped proteins act together to directly regulate wing- specific gene expression in Drosophila.Genes & Development 12,3900-3909.

Kango-Singh M, NoloR, Tao C, Verstreken P. Hiesinger PR, Bellen III, and Haider G (2002). Sharpei mediates cell proliferation arrest during imaginal disc growth in Drosophila. Development 129, 5719-5730.

 

Uit het jury-rapport:

Georg Halder is an excellent scientist who has made many important and novel contributions to growth control, in particular of the regulation of the Hippo pathway. He has also shown important functions for Dachsous, and in particular the intracellular domain of Dachsous, as a growth regulator. He and others have shown that the cell polarity protein Crumbs is a regulator of the Hippo pathway. He has also initiated a number of collaborations of high quality. At present his collaborations are primarily in the US, but upon moving to Leuven, the number of European collaborations will undoubtedly increase. His ability to interact with human genetic systems will also benefit as a result of this relocation.

In the granted project, the discovery of novel growth control and cancer mechanisms, Dr. Halder plans to continue his cutting-edge studies on how growth control is regulated by the Hippo pathway using genetic approaches in Drosophila. He also intends to expand his interests by examining growth control by the PI3K pathway, and by supplementing his genetic approaches with biochemical proteomic studies. The plans outlined can lead to exciting new discoveries.